Download Written Testimony Comments as of 01 27 2016

JAN-25-2018 MON 01:32 P11 UH ARTS
HUMANITIES
FAX NO. 808 956 9085
P. 01/02
CoIlcg üí Ar1 and Humanities
Offiei o th Dean
UNIVERSITY
of friAWAI’I
MANOA
Public Testimony
January 24, 20 16
Undersigned Deans
University of l-lawai’i at Mãnoa
Board of Regents
University of Hawaii
Bachrnan 209
2444 Dole Street
Honolcilu, HI 96822
Regarding: Public Testimoni on Status of Design and Implementation Plan for
System and UI-I Mänoa Orgarizational Changes and Consolidations to Improve the
Efficiency and Effectiveness f Suppott Services
Deal’ Regent Randolph G. More:
We, the undersigned Deans et the University of Hawaii at Mnoa (UT-TM), welcome
the opportunity to testify abàut the ongoing discussions regarding UI-TM and
organizational changes.
We strongly endot’se Presidnt Lassner’s request that the Mãnoa Chancellor be a
separate position from that (the UH System President. The UI-TM requires strong
and visionary leadership in dur endeavor to build our reputation as a global
research university that sim9ltaneously serves the needs of our students and
community. We urge you to support his intent to proceed with a search for a
Chancellor.
UI-TM is at a critical jLtncture, having undergone sharp budget constriction and
transitional leadership. We face structural budget challenges as well as deferred
investments in academic programs and the campus’ physical infrastructure.
Morale has suf’fered at muItile levels, as students, faculty, and our community have
indicated to us. The UI-TM reduires Strong leadership to address a myriad of issues
as the campus adapts to new fiscal realities and contemporary and changing
educational demands.
Against this backdrop, UI-TM requires leadership in a Chancellor to deliver
outstanding academic progrrns and innovative research.
2500 Campus Ruad, I Iawaii HaIl 302
HnnluIu, Hawal’I 9b822
Telephunu: (OD1 956-64C0
Fax: (806) 956-9005
An Equal üppnr in ity/At0rnativu Action lnstitutinn
JAN—25—2016 MON 01:32 PM UH ART$
HUMANITIES
FAX NO. 808 956 9085
We further recommend that the UHM undergoes a process of reorganization to
deliver more effective services. We recognize the benefits of streamlining
admjnisttation to better serve our students, promote researeft and serve the public.
We acknowledge the need to be more accountable and to modernize our processes
concerning budget and acalemic planning.
We, the Deans, commit to working with a Chancellor and our faculty in a spirit of
shared governance to these ends:
•
a
a
Align academic and student affairs
Upgrade functionality within human resources, fiscal, and campus and
facilities planning.
Review college and’school administration to promote efficient delivery of
modern academic programs
We ask yoct to support President Lassner’s request to proceed with a search for a
Chancellor. We are committed to a better UHM for our students, community, and
s ta to.
P. 02/02
1/26/2016
University of Hawaii Mail ­ Written Testimony to the BOR Independent Audit Committee and full BOR
Board of Regents <[email protected]>
Written Testimony to the BOR Independent Audit Committee and full BOR
Ioannis Stasinopoulos <[email protected]>
To: [email protected]
Tue, Jan 26, 2016 at 12:32 PM
Dear Sir/Madam,
Below I attach written testimony that I ask be included as part of the record of the audit committee. As the
Center's grant coordinator responsible for monitoring the grants portfolio of UHCC Members and Faculty, I
ask that my testimony be considered by the Audit committee and any upcoming full BOR meetings
discussing the UH Cancer Center.
The verbal testimony I wish to provide to the audit committee on 01/27/2016 is shown on page 2 of the
attached PDF file.
Best Regards,
Ioannis Stasinopoulos, Ph.D.
Research Grants Coordinator
University of Hawaii Cancer Center
701 Ilalo St., Rm 310
Honolulu, HI 96813
Tel: (808) 356­5768
Fax: (808) 586­0115
BOR Testimony ­ 012616­IS_FINAL.pdf
734K
https://mail.google.com/mail/u/0/?ui=2&ik=5a046f4367&view=pt&search=inbox&msg=1528011036f751be&siml=1528011036f751be
1/1
UHCC Grants Office
01/26/2016
University of Hawai‘i Cancer Center Grants Office
Table of Contents
Page
Title Page and Table of Contents..........................................................................................................
Verbal Testimony..................................................................................................................................
Section A. Warbird – Navigant Report Error regarding UHCC Grants Portfolio.....................................
Section B. UHCC Faculty Cancer Grant Portfolio Comparison between 2016 and 2012.......................
Table 1: 2016 & 2012 UHCC Cancer Grant Funding Comparison.........................................................
Table 2: 2016 UHCC Cancer Grants Portfolio (Vetted by EAC in January 2016)...................................
Table 3: 2012 UHCC Cancer Grants Portfolio (Vetted by NCI in February 2012)...................................
1
2
3
4
4
5
11
Page 1 of 16
UHCC Grants Office
01/26/2016
Verbal Testimony
My name is Ioannis Stasinopoulos and I speak before you as the Center’s P30 Coordinator. Before coming to
Hawai‘i in June 2013, I was a postdoctoral fellow and junior faculty at the Johns Hopkins University School of
Medicine performing research on breast cancer.
A significant part of my work involves the monitoring of grants and publications awarded to the Center. In other
words my job is to work together with the Director and the Senior Leaders to monitor our researchers’ productivity
with respect to our designation.
University of Hawai‘i Cancer Center researchers are bringing more clinical, basic, and population science
research funds than ever before.
The sponsor’s expectation is that our scientists translate nationally-competitive hypothesis-driven research into
clinical, basic, and population interventions within our state, nationally, and beyond.
Significant progress is being made in these areas as evidenced by new grants and publications that continue
the progress in cancer diagnoses, disparities, and underserved minority population cancer prevention and
control.
Some examples of such research include:
Understanding of the cultural behaviors of the people of Hawai‘i that may pose barriers to vaccination
against cervical cancer,
Large-scale efforts to understand the role of obesity in causing cancer in the multi-ethic populations,
The development of diagnoses for bladder and liver cancer,
The re-invigorated clinical research treatments made available to people who cannot travel to the
mainland by the University of Hawai‘i Cancer Center.
In my written testimony I make available summary and detailed comparison tables showing our researchers’
cancer awards now and at the time of our last P30 renewal. The choice that faces the University and the state
is stark: as you go through these grant awards one by one, I urge you to consider that following the loss of our
designation the significant majority of this research will either be lost immediately or fade away after the
divestment under consideration. If our Center does not gain additional support and loses the NCI designation,
our most accomplished researchers who make positive impacts to our community will leave towards more
supportive environments.
While the total funding brought in by our researchers has increased since 2012, so have the expectations for the
renewal of our designation. The Center’s investigators annually apply to bring approximately $100 M of federal
funds to the state of Hawai‘i. President Obama has recently announced a significant funding initiative to cure
cancer. As the federal government makes more funds available, our designation enables our researchers to
more successfully compete for the increasing funds. At this defining moment in the history of cancer research,
the state of Hawai‘i and our flagship University must answer in a positive and forward looking way. Thank you
for your time.
Page 2 of 16
Section A. Warbird – Navigant Report Error regarding UHCC Grants Portfolio
UHCC Grants Office
01/26/2016
To whom it may concern,
The Warbird - Navigant report1 regarding the UHCC business plan claims that UHCC faculty had 250 grants in
FY13 and that this number dropped to 180 in FY15 (Appendix A, paragraph 7). However, in appendix E,
paragraph 6, the consultant firm states that it “did not conduct a thorough financial review of selected individual
grants and awards, much less the entire portfolio”.
More importantly, publicly available UH reports show instead that in FY15 UHCC Faculty held 74 grants2, up 6
from FY13 when UHCC Faculty held 68 grants3. UH grant accounting numbers are consistent with internal UHCC
grant office portfolio reporting required for the NCI designation and presented in pages 4-10 of this report.
As a comparison to our current relevant grants portfolio we provide the Center’s 2012 grants tables, as reviewed
by the NCI, at the time of the Center’s last competing renewal in 2012.
We therefore ask all interested parties to disregard the Warbird – Navigant grant count as erroneous.
1. http://www.hawaii.edu/offices/bor/audit/materials/201601271400/III.A.1._University_of_Hawaii_at_Manoa_
Cancer_Center_Report_and_Business_Plan.pdf
2. http://www.ors.hawaii.edu/files/2015_Annual_Report_Extramural_Awards&Expenditures.pdf
3. http://www.ors.hawaii.edu/files/2013_Annual_Report_Extramural_Awards&Expenditures.pdf
Page 3 of 16
UHCC Grants Office
01/26/2016
Section B*. UHCC Faculty Cancer Grant Portfolio** Comparison between 2016 and 2012
*Detailed grant tables shown in section B represent those awards that the designated Research Program
Directors and Administration have agreed as bearing relevance to cancer.
** The tables below show the annual funding income of cancer grants active on 12/01/15 and 12/31/11 vetted
during the Center’s External Advisory Committee (EAC) annual site visit in January, 2016 and the National
Cancer Institute’s (NCI) review and evaluation in February, 2012, respectively.
Table 1: 2016 & 2012 UHCC Cancer Grant Funding Comparison
2016 UHCC Faculty Cancer Grant Funds:
$22,713,574
2012 UHCC Faculty Cancer Grant Funds:
$19,878,036
Page 4 of 16
UHCC Grants Office
01/26/2016
Table 2: 2016 UHCC Cancer Grants Portfolio (Vetted by EAC in January 2016)
PrincipaI
Investigator
Specific
Funding
Source
Project
Start
Date
Project
End Date
Owen J (PAVIR)
Bantum E
NCI VIR-Palo
Alto
7R21CA166029-02
9/26/2013
8/31/2016
Impact of Social Networking on Dose and Effects of
Cancer Survivorship Trials
Berenberg J
Morris P
NCI
5UG1CA189804-02
8/1/2014
7/31/2019
Hawai'i Minority /Underserved NCORP
Carbone M
NCI
1R01CA198138-01
7/6/2015
6/30/2020
Germline Bap1 Mutations And Malignant Mesothelioma:
Mechanisms And Early Detection
349,988
Fagan P
NIDA VCU
5P50DA036105-03
9/1/2015
8/31/2017
PROJECT 4: Quantitative And Qualitative Methods For
MRTP Evaluation P219-245
90,172
Fei P
NCI
5R01CA136532-06
7/1/2009
5/31/2016
Roles of Fanconi Anemia Pathway in Bladder
Tumorigenesis
141,979
Fei P
NCI
5R01CA188251-02
7/1/2014
6/30/2019
Molecular Insights into the Fanconi Anemia Tumor
Suppressor Signaling Pathway
317,475
Franke A
NCI Vanderbilt
University
5R03CA189455-02
9/1/2015
8/31/2016
Effect of Magnesium treatment on Vitamin D Resistance
Ward W Garmire
L
NIGMS
2P20GM103457-06A1
7/1/2014
6/30/2019
Project 3: Linking Maternal Obesity And Offspring
Cancer Risks Through Integration Cord Blood Stem Cell
Methylome And Transcriptome
Hedges J
NCI
5P30CA071789-16
7/1/1994
6/30/2017
University of Hawaii CCSG
Hedges J
NCI
3P30CA071789-16S1
7/1/1994
6/30/2017
University of Hawaii CCSG
Hedges J
NCI
3P30CA071789-16S2
7/1/1994
6/30/2017
University of Hawaii CCSG
Hedges J
NCI
3P30CA071789-16S3
7/1/1994
6/30/2017
University of Hawaii CCSG
Hernandez B
NCI JHU
5R01CA140311-05
4/19/2011
3/31/2016
Multicenter Genetic, Epigenetic & Expression Analysis
of DCIS Outcome Predictors
Project Number
Page 5 of 16
Project Title
Annual
Project Total
Costs ($)
96,246
748,896
20,711
267,750
1,361,692
114,745
650,078
177,700
5,000
UHCC Grants Office
01/26/2016
Hernandez B
NCI
HHSN26100004
8/15/2015
8/14/2016
Patterns Of Care/Quality Of Care Study: Diagnosis Year
2014
Hernandez B
NCI
HHSN261201300009I
8/1/2013
7/31/2017
Surveillance, Epidemiology, And End Results (SEER)
Hernandez B
NCI
HHSN261201300009I3937521
9/17/2015
9/16/2017
SEER-linked Virtual Tissue Repository (VTR)
Jia W
NCI
1U01CA188387-01
8/1/2015
7/31/2020
Gut Microbiota Mediated Bile Acid Alterations In Hepatic
Carcinogenesis
536,813
Kwee S Okimoto
G
NCI
5R01CA161209-05
7/1/2011
4/30/2017
Functional Genomics and Molecular Imaging of Liver
Disease and Cancer
411,672
Le Marchand L
Haiman C (USC)
NHGRI USC
5U01HG007397-03
9/1/2013
5/31/2017
Epidemiologic Studies Of Putative Functional Variation
In Multiethnic Cohort
198,468
Le Marchand L
NCI University of
Minnesota
5P01CA138338-05
4/1/2010
3/31/2016
Multiethnic Genome Scan Of Metabolic Phenotypes
Le Marchand L
Haiman C
Wilkens L
NCI
5U01CA164973-04
9/1/2012
8/31/2017
Understanding Ethnic Differences In Cancer: The
Multiethnic Cohort Study
Le Marchand L
NCI Stanford
5UM1CA167551-03
5/1/2013
4/30/2018
Colon Cancer Family Registry Cohort
Le Marchand L
NCI
5P01CA168530-04
9/1/2012
8/31/2017
Obesity, Body Fat Distribution, And Cancer Risk In The
Multiethnic Cohort
4,121,831
Lim U
NIDDK
1R21DK105413-01
9/1/2015
8/31/2017
Brain-Gut Microbiome-Visceral Adiposity Relationships
In Multiethnic Adults
237,470
Loo L
NCI
5R21CA176555-02
7/8/2014
6/30/2016
Obesity And Igf-Axis Activation In Native Hawaiian
Women With Breast Cancer
199,665
Matter M
NIGMS
5R01GM104984-04
9/1/2012
8/31/2017
Regulation of Endothelial Permeability in Sepsis
Park S
NCI Health
Research Inc.
5P01CA151135-05
8/1/2011
7/31/2016
Epidemiology Of Breast Cancer Subtypes In African
American Women: A Consortium
Ramos J Ji J
NCI
5R01CA096841-10
8/1/2002
4/30/2016
Regulation of Tumor Promotion by RASGRP1
Page 6 of 16
52,508
1,724,464
138,367
451,684
3,879,211
132,713
330,568
32,699
284,811
UHCC Grants Office
01/26/2016
Rosser C
NCI Nonagen
Bioscience
Corporation
5R44CA173921-03
8/6/2013
2/29/2016
Development of Molecular Assays for Non-Invasive
Bladder Cancer Detection
Turkson J
NCI
5R01CA161931-04
8/1/2012
5/31/2017
Salicylic acid-based small-molecule STAT3 inhibitors for
anticancer therapy
Vogel C Palafox
N Ward D
NCI
2U54CA143727-06
9/28/2009
8/31/2020
University of Guam/Cancer Research Center of Hawaii
Partnership (1 of 2)
Wilkens L
NCI Cancer
Prevention
Institute of
California
7R01CA154644-03
9/1/2011
8/31/2016
Obesogenic Environment: Impact On Breast, Colorectal,
And Prostate Cancer Risk
11,271
Wills T Gibbons F
NCI
5R01CA153154-05
7/1/2010
4/30/2016
Self-Control as a Moderator for Effects of Mass Media
on Adolescent Substance Use
87,010
Wills T Ernst T
NIDA
1U01DA041117-01
9/30/2015
5/31/2016
Adolescent Brain Cognitive Development (ABCD)
Prospective Research in Studies of Maturation (PRISM)
Consortium
Wills T
NCI Dartmouth
College
2R01CA077026-15A1
9/30/1997
4/30/2018
Visual Media Influences on Adolescent Smoking
Behavior
42,393
Yang H
DOD
W81XWH-13-1-0175
8/1/2013
7/1/2016
Mesothelioma: Identification of the Key Molecular
Events Triggered by BAP1
50,782
Yang H
NCI
5R01CA160715-05
7/28/2011
5/31/2016
The Role of HMGB1 in the pathogenesis of
Mesothelioma
Yu H
NCI
5R01CA138698-05
8/1/2010
5/31/2016
Epidemiologic Study Of Hepatocellular Carcinoma In
The US
Garmire L
NIEHS
1K01ES025434-01
9/29/2014
6/30/2019
An Integrative Bioinformatics Approach To Study Single
Cancer Cell Heterogeneity
Carbone M Yang
H
The V
Foundation
N/A
10/31/2012
10/1/2016
HMGB1, A Biomarker for Mineral Fiber Exposure and
Detection of Malignant Mesothelioma
$23,835
Garmire L
Hawaii
Community
Foundation
14ADVC-64566
5/15/2014
11/14/2016
Using Next Generation Sequencing Technology To
Detect Circulating MicroRNAs As Diagnostic Biomarkers
Of Liver Cancer
$16,942
Ramos J
Hawaii
Community
Foundation
15ADVC-74405
5/11/2015
11/10/2016
PEA-15 Regulation of Endocytic Trafficking in Cancer
Page 7 of 16
37,500
480,634
1,015,895
1,388,507
311,250
1,460,631
180,368
32,270
UHCC Grants Office
01/26/2016
Myra W. and
Jean Kent
Angus
Foundation
115054959
Acoba J
Biothera
BT-CL-PGG-CRC1031
Acoba J
Eli Lilly
Acoba J
Matter M
9/23/2015
9/15/2016
The Role of Bit1 in Neuroblastoma
A Phase 3 Open Label Randomized, Multicenter Study
Of Imprime PGG In Combination With Cetuximab
(Erbitux) In Subjects With Recurrent Of Progressive
KRAS Wild Type Colorectal Cancer
A Phase I Study Of LY2784544 Testing Alternative
Dosing Regimens In Patients With Myeloproliferative
Neoplasms
Prospective International Observational Cohort NonComparative Study Describing The Safety And
Effectiveness Of ZALTRAP Administered In
Combination W/ FOLFIRI For The Treatment Of
Patients W/ Metastatic Colorectal Cancer...
Modular Phase II Study To Link Targeted Therapy To
Patients W/ Pathway Activated Tumors: Module 8 Lee011 For Patients W/ Cdk4/6, Cyclin D1/3 Or P16
Activated Tumors
Phase 1/2 Study of PF-03084014 in Combination with
Gemcitabine and Nab-Paclitaxel in patients with
previously untreated Metastatic Pancreatic Ductal
Adenocarcinoma
Amgen: A Phase 3 Randomized, Double-Blind,
Placebo-Controlled, Multi-Center Study Of AMG 386
With Paclitaxel And Carboplatin As First-Line Treatment
Of Subjects With FIGO Stage III-IV Epithelial Ovarian,
Primary Peritoneal Or Fallopian Tube Cancer
A Phase III, Randomized, Double Blind, Placebo
Controlled, Multicentre Study Of Olaparib Maintenance
Monotherapy In Patients With BRCA Mutated Advanced
(FIGO Stage III-IV) Ovarian Cancer Following First Line
Platinum Based Chemotherapy, D0818C00001
A Randomized, Double-Blind, Multi-Center Phase 3
Study Of ADI-PEG 20 Plus Best Supportive Care (BSC)
Versus Placebo Plus BSC In Subjects With Advanced
Hepatocellular Carcinoma (HCC) Who Have Failed Prior
Systemic Therapy
5/30/13
6/30/2020
13X-MC-JHTC
4/22/2013
4/21/2017
Sanofi
OB13597
10/24/2014
6/30/2019
Acoba J
Novartis
CLEE11XUS03
2/26/2015
12/31/2017
Acoba J
Pfizer
A8641019
7/31/2014
12/31/2017
Carney M
Amgen/Gynecol
ogical Oncology
Group
GOG 3001, 806-01
2/14/2013
10/30/2017
Carney M
AstraZeneca/Gy
necological
Oncology Group
GOG 3004,
D0818C00001
4/10/2014
3/27/2017
Cho J
Polaris
CRCH-1104
11/3/2011
9/30/16
Cho J
Onconova
AGICC 11PAN01
1/18/2012
9/30/2016
Phase II/III Stdy Eff & Sfty Of Gem
Cho J
Gennentech
Roche
BO22589
4/7/2011
6/1/2016
Phase III Eval The Sfty Of T-Dm1
Chong M
Prometheus
10PLK13
6/21/2015
6/20/2020
Proleukin Observational Registry to Evaluate the
Treatment Patterns and Clinical Response in
Malignancy
Page 8 of 16
53,000
31,191
31,256
11,741
3,213
22,086
61,118
36,959
36,238
40,091
540
-
Fukumoto J
Millennium
C16014
1/29/2015
8/6/2019
Fukumoto J
Bristol MyersSquib
CRCH-1101
12/13/2011
6/30/2016
Miyashiro M
Jarrod Holmes
ML25749
1/6/2014
11/29/2016
Miyashiro M
PUMA
Biothechnology
PUMA-NER-1301
2/28/2014
3/9/2019
Rosser C
Altor BioScience
CA-ALT-803-01-14
8/20/2014
6/27/2019
Rosser
Bayer
Reassure 16913
4/15/2015
4/17/2020
Tamura D
Exelixis
XL184-309
4/23/2014
4/2/2019
Wilkinson R
Wilkinson R
Wilkinson R
Millennium
Pharmaceuticals
/Children's
Hospital of
Philadelphia
(CHOP)/Children
's Oncology
Group (COG)
Millennium
Pharmaceuticals
/Children's
Hospital of
Philadelphia
(CHOP)/Children
's Oncology
Group (COG)
Hoffmann-La
Roche/Children's
Hospital of
Philadelphia
(CHOP)/Children
's Oncology
Group (COG)
A Phase 3, Randomized, Double-Blind, Multicenter
Study Comparing Oral MLN9708 + Lenalidomide &
Dexamethasone Vs. Placebo + Lenalidomide &
Dexamethasone In Adult Patients W/ Newly Diagnosed
Multiple Myeloma
Studying Interventions For Managing Patients With
Chronic Myeloid Leukemia In Chronic Phase: The 5Year Prospective Cohort Study (BMS SIMPLICITY)
Combination Immunotherapy With Herceptin And The
HER2 Vaccine E75 In Low And Intermediate HER2Expressing Breast Cancer Patients To Prevent
Recurrence
A Study Of Neratinib Plus Capecitabine Versus
Lapatinib Plus Capecitabine In Patients With HER2+
Metastatic Breast Cancer Who Have Received Two Or
More Prior HER2 Directed Regimens In The Metastatic
Setting
A Study Of Intravesical Bacillus Calmette-Guerin (BCG)
In Combination With Alt-803 In Patients With BCGNaive Non-Muscle Invasive Bladder Cancer
REASSURE - Radium-223 alpha Emitter Agent in
Safety Study in mCRPC popUlation for long-teRm
Evaluation
A Phase 3, Randomized, Double-Blind, Controlled
Study Of Cabozantinib (XL184) Vs. Placebo In Subjects
W/ Hepatocellular Carcinoma Who Have Received Prior
Sorafenib
AAML1031
4/11/2013
4/11/2023
A Phase III Randomized Trial For Patients With Senovo
AML Using Bortezomib (NSC# 681239) And Sorafenib
(BAY 43-9006, NSC# 724772) For Patients W Allelic
Ratio FLT3/ITD
AALL07P1
2/15/2012
2/15/2022
A Phase II Pilot Trial Of Bortezomib (PS-341, VELCADE
IND 58,443) In Combination With Intensive Re-
ANHL1131
2/15/2012
2/15/2022
Induction Therapy For Children With Relapsed Acute
Lymphoblastic Leukemia (ALL) And Lymphoblastic
Page 9 of 16
UHCC Grants Office
01/26/2016
21,905
5,620
-
29,742
43,786
-
45,924
-
-
9,000
Wilkinson R
Wilkinson R
Bristol-Myers
Squibb
Company/Childr
en's Hospital of
Philadelphia
(CHOP)/Children
's Oncology
Group (COG)
Children's
Hospital of
Philadelphia
(CHOP)/Children
's Oncology
Group
(COG)/Sanofi/G
enzyme
UHCC Grants Office
01/26/2016
BMS CA180-372
(COG-AALL1122)
4/5/2013
4/5/2023
Lymphoma (LL)
AALL1131Sanofi/Genzyme
2/23/2015
1/3/2017
Intergroup Trial For Children Or Adolescents With B-Cell
NHL Or B-AL: Evaluation Of Rituximab Efficacy And
Safety In High Risk Patients
-
Totals
Page 10 of 16
15,500
22,713,574
UHCC Grants Office
01/26/2016
Table 3: 2012 UHCC Cancer Grants Portfolio (Vetted by NCI in February, 2012)
Principle
Investigator
Funding
Agency
Grant Number
Start
Date
End
Date
Project Title
Annual
Project Total
Costs ($)
Albright, Cheryl L
NCI
5R01 CA115614-04
09/29/07
07/31/12
Physical Activity in Women with Infants
-
Albright, Cheryl L
NCI
3R01CA115614-03S1
08/01/09
07/31/12
Administrative Supplements for: Physical Activity in Women
with Infants
-
Albright, Cheryl L
NIDA/Klein
Buendel, Inc.
5R42DA031402-03
01/01/08
08/31/13
A Home Exercise Program for Women with Infants and
Young Children
39,000
Ambrosone,
Christine (HRI)/
Kolonel, Laurence
(UHCC)
NCI
1P01CA151135-01A1
08/01/11
07/31/16
Epidemiology of Breast Cancer Subtypes in African American
Women: A Consortium
32,366
Amos,
Christopher (MD
Anderson)/ Le
Marchand, Loic
(UHCC)
NCI
1U19CA148127-01
07/09/10
06/30/14
Transdisciplinary Research in Cancer of the Lung (TRICL)
Bachmann, Andre
NCI
5R01CA111419-04
REV
08/01/06
06/30/12
Role of Polyamines in MYCN-Amplified Neuroblastoma
-
Bachmann, Andre
Hawaii
Community
Foundation
09ADVC-45411
11/04/09
05/05/12
In Vivo Efficacy of Novel Proteasome Inhibitors in
Neuroblastoma
-
Berenberg, Jeffrey
NCI
5U01CA063844-18
08/01/94
05/30/15
Hawaii Minority-Based Clinical Community Oncology
Program
Berenberg, Jeffrey
Southwest
Oncology Group
CA37429
05/18/07
05/31/13
Southwest Oncology Group Purchase Services Agreement:
SELECT & Ancillary Studies
Carbone, Michele
NCI
5P01CA114047-05
09/15/06
08/31/12
Pathogenesis of Mesothelioma
Carbone, Michele
NCI
3P30CA071789-12S9
07/01/97
06/30/12
Cancer Research Center of Hawaii
720,185
Carbone, Michele
NCI
3P30CA07178912S6/ARRA
09/28/09
09/27/12
Cancer Research Center of Hawaii
-
Carbone, Michele
NCI
3P30CA07178912S7/ARRA
09/30/09
09/28/12
Cancer Research Center of Hawaii
-
Cheng, Iona
NCI
5R01CA140636-03
09/28/09
07/31/13
Characterizing Mitochondrial NDA Susceptibility to Breast,
Colorectal, and Prostate Cancer
467,992
Cheng, lona
NCI
1R01CA154644-01
09/01/11
07/31/15
Obesogenic Environment: Impact on Breast, Colorectal, and
Prostate Cancer Risk
344,827
Cheng, lona
The V
Foundation
MISC 2009VScholar
11/01/09
10/31/12
Identifying IGF1 Genetic Susceptibility Variants for Prostate
Cancer in African Americans
Page 11 of 16
188,824
542,939
22,900
-
-
UHCC Grants Office
01/26/2016
Cho, Jonathan K
Genentech, Inc.
CRAProt
B022589/TDMI4788G
11/02/10
11/01/13
A Randomized, 3 Arm, Multicentre, Phase III Study to
Evaluate the Efficacy and the Safety of T-DM1C
13,495
48,639
160,806
Cho, Jonathan K
Onconova
Therapeutics
N/A
10/01/11
09/30/13
A Phase ll/lll, Multi-Center, Randomized, Controlled Study to
Compare the Efficacy and Safety of Gemcitabine Alone vs.
ON 01910.Na Combine with Gemciitabine in Patients with
Previously Untreated Metastatic Pancreatic Cancer" Protocol
Number 04-22
Cho, Jonathan K
Polaris
N/A
11/03/11
09/30/13
A Randomized, Double-Blind, Multi-Center Phase 3 Study of
ADI-PEG 20 Plus Best Supportive Case (BSC) Versus
Placebo Plus BSC
Chu, Wen-Ming
NIAIDS
7R01AI054128-07
04/01/09
03/31/14
Mechanism of Activation of Innate Immunity by ISS-DNA
330,785
Fei, Peiwen
NCI
7R01CA136532-04
07/01/09
05/31/14
Roles of the Fanconi Anemia Pathway in Bladder
Tumorigenesis
285,246
Gaudino,
Giovanni
Hawaii
Community
Foundation
10ADVC-47420
09/01/10
09/01/12
Role of tumor necrosis factor (TNF) signaling in chrysotileasbestos induced mesothelioma
100,000
Goodman, Marc
NCI
2R01 CA058598-13
08/15/93
05/31/13
Collaborative Genetic Study of Ovarian Cancer Risk
482,794
Goodman, Marc
NCI
HHSN261201000037C
AMDT 0001
10/01/14
09/30/15
Patterns of Car/Quality Care Diagnosis Year 2009
Goodman, Marc
NCI
HHSN261201000171
03/19/10
03/18/12
The Cancer Genome Atlas (TCGA)
146,529
Goodman, Marc
NCI
HHSN261201000171
MOD 0001
03/19/10
03/18/12
The Cancer Genome Atlas (TCGA)
47,536
Goodman, Marc
NCI
HHSN261201000037C
AMDT2
08/01/11
07/31/12
Surveillance, Epidemiology and End Results (SEER)
Hannun, Yusuf
(MUSC) /
Kawamori,
Toshihiko (UHCC)
NCI
5P01CA097132-09
07/01/02
07/31/13
Sphingolipids in Cancer Biology and Therapy
15,837
Hecht, Stephen
(UMN)/ Le
Marchand, Loic
(UHCC)
NCI
5P01C A138338-02
04/01/10
03/31/15
Mechanisms of Ethnic/Racial Differences in Lung Cancer Due
to Cigarette Smoking
78,256
Henderson, Brian
(USC)/ Le
Marchand, Loic
(UHCC)
NCI
U01 CA098758-08
06/05/03
07/31/12
Characterizing Genetic Susceptibility to Breast and Prostate
Cancer; the BPC3
63,271
Henderson, Brian
(USC)/ Le
Marchand, Loic
(UHCC)
NCI
U01 CA136792-03
03/25/09
02/28/12
A Genome Wide Association Study of Prostate Cancer in
African Americans; Subaward from USC
Hernandez,
Brenda
Association of
American
MM-1132-10/10
09/30/09
09/29/12
Evaluation of genital self-sampling for HPV detection in males
Page 12 of 16
47,222
1,207,758
203,957
-
UHCC Grants Office
01/26/2016
Medical
Colleges
Herzog, Thaddeus
NCI
5R01CA120799-05
09/27/07
07/31/12
Testing Alternative Stage Models of Smoking Cessation: An
Intervention Study
221,160
Kawamori,
Toshihiko
NCI
5R01CA124687-05
01/01/09
12/31/13
The Sphingolipid Pathway in Colon Cancer Chemoprevention
271,722
Kolonel, Laurence
NCI
5R37CA054281-19
01/01/83
02/28/13
Multiethnic Cohort Study of Diet and Cancer (VDPP: Rarer
Cancers)
Kolonel, Laurence
NCI
3R37CA54281-17S1
09/01/09
08/31/12
Multiethnic Cohort Study of Diet and Cancer; Administrative
Supplement
-
Kolonel, Laurence
NCI
5P01CA33619-22
01/01/83
08/31/12
Molecular Epidemiology of Nutrition and Cancer in the
Multiethnic Cohort Study
-
Kwee, Sandi
NCI
5R21CA139687-02
07/01/09
06/30/12
Treatment Effects on tumor 18F-Choline Metabolism in
Advanced Prostate Cancer
-
Kwee, Sandi
(QMC) / Okimoto,
Gordon (UHCC)
NCI
1R01CA161209-01
07/01/11
04/30/16
Functional Genomics and Molecular Imaging of Liver Disease
and Cancer
Kwee, Sandi
(QMC) / Okimoto,
Gordon (UHCC)
NCI
1R01CA161209-01
07/01/11
04/30/16
Functional Genomics and Molecular Imaging of Liver Disease
and Cancer
Kwee, Sandi
(QMC)/ Okimoto,
Gordon (UHCC)
NCI
1R01CA161209-01
07/01/11
04/30/16
Functional Genomics and Molecular Imaging of Liver Disease
and Cancer
Lau, Alan
Hawaii
Community
Foundation
11ADVC-49235
05/18/11
11/18/12
Regulating the Degradation of Connexin43 Through the
Proteasomal Pathway
Le Marchand, Loic
NCI
5U24CA074806-13
06/25/97
08/31/12
The Colon Cancer Family Registry: Hawaii
Le Marchand, Loic
NCI
5R01CA126895-04
09/01/08
07/31/13
Whole Genome Scan for Modifier Genes in Colorectal Cancer
Le Marchand, Loic
NCI
5R01CA129063-04
09/15/08
07/31/12
Inflammation and Innate Immunity Genes and Colorectal
Cancer Risk
Le Marchand, Loic
NCI
3R01CA126895-02S1
09/30/09
09/29/12
Whole Genome Scan for Modifier Genes in Colorectal Cancer
Le Marchand, Loic
NHGRI
5U01HG004802-04
07/01/08
05/31/12
Epidemiology of Putative Causal Variants in the Multiethnic
Cohort
1,599,270
Le Marchand, Loic
NHGRI
3U01HG004802-02S1
09/30/09
08/31/12
Epidemiology of Putative Causal Variants in the Multiethnic
Cohort; Supplement
-
Le Marchand, Loic
World Cancer
Research Fund
RFA09-149
07/01/10
06/30/13
Validation of the Hair as a Tissue to Biomonitor PhIP, a
Carcinogenic Heterocyclic Aromatic Amine
577,394
Lim, Unhee
AICR
09A143
01/01/10
12/31/11
Dietary Intake of Choline and Betaine, Related Genetic
Polymorphisms and the Rick of CRC
165,000
Lindor, Noratane
(Mayo Clinic)/ Le
NCI
3U24CA074800-11S1
09/01/09
08/31/12
The Familial Colorectal Neoplasia Collaborative Group/
Subward Agree. Mayo Clinic Rochester
6,836
Page 13 of 16
2,285,139
452,004
50,000
425,502
1,853,251
565,702
-
UHCC Grants Office
01/26/2016
Marchand, Loic
(UHCC)
Lorenzo, Patricia
NCI
2R01CA096841-06A2
08/01/02
04/30/16
Regulation of Tumor Promotion by RasGRPI
Lorenzo, Patricia
NCI
1R03C A165128-01
12/01/11
11/30/13
Ras Activation Pathways in UVR-lnduced Epidermal
Transformation
Lorenzo, Patricia
Hawaii
Community
Foundation
09ADVC-45412
11/04/09
11/04/11
Mechanistic and structural studies of the fungal derivative
terspetacin as an antiangiogenic agent - CRCH
-
Maskarinec,
Gertraud
NCI
5R01CA080843-09
09/01/99
02/28/12
Effects of Soy on Estrogens in Breast Fluid and Urine
-
Maskarinec,
Gertraud
NCI
1R03 CA135699-02
03/01/09
02/28/12
A Pooled Analysis of Mammographic Density and Breast
Cancer
-
Maskarinec,
Gertraud
NCI
1R03CA150041 -02
04/01/10
03/31/12
Urinary Estrogen Metabolites in A 2-Year Soy Trail Among
Premenopausal Women
66,300
Matter, Michelle
Hawaii
Community
Foundation
11ADVC-49236
05/18/11
11/18/12
Bit-1 Signaling in Cardiovascular Disease
50,000
Owen, Jason
(LLU)/ Bantum,
Erin (UHCC)
NCI
1R21CA143642-02
08/05/10
07/31/12
Use of Natural Language Processing to Identify Markers of
Coping
60,050
Ramos, Joe
NIGMS
5R01GM088266-02
09/30/10
08/31/14
RSK2 regulates integrin-mediated adhesion and migration
282,150
Ramos, Joe
Hawaii
Community
Foundation
09AVSBGF-44279
05/27/09
12/31/11
RSK2 modulates cell adhesion
Ryazanov, Alexey
(UMDNJ)/ Fleig,
Andrea (UHCC)
NIGMS
5P01GM078195-04
05/01/07
04/30/12
Regulation of metal ion homeostasis by channel kinases
Sargent, James
(Dartmouth)/
Wills, Thomas
(UHCC)
NCI
R01CA077026
05/01/11
04/30/12
Visual Media Influences on Adolescent Smoking Behavior
35,132
Sargent, James
(Dartmouth)/
Wills, Thomas
(UHCC)
NIAAA
2R01AA015591
08/01/10
07/31/12
Media Influences on Early Onset Alcohol Use
35,779
Simons, Jeffrey
(USD)/ Wills,
Thomas (UHCC)
NIAAA
1R01AA17433-01A2
06/01/09
05/31/12
Self-Control and Alcohol Problems: Psychological
Mechanisms
Sumida, Kenneth
NSABP
Foundation
TIND-118
12/01/97
01/31/13
NSABP Foundation - Master 118 RCUH
60,000
Sumida, Kenneth
NSABP
Foundation
TIND118-B43
12/01/07
01/31/13
Addendum to TIND -118 Industrial Master Purchased
Services Agreement, Subpart B-43: GENENTECH
21,600
Page 14 of 16
284,811
75,000
-
391,600
-
UHCC Grants Office
01/26/2016
Tsai, Naoky
NIH
5U01DK082863-02
09/30/08
05/31/15
Hepatitis B Clinical Research Network Clinical Center
Michigan-Hawaii Consortium
Turesky, Robert
(Wadsworth
Center)/ Le
Marchand, Loic
(UHCC)
NCI
5R01CA122320-05
09/11/07
07/31/12
Chemical Markers of Heterocyclic Aromatic Amines for
Human Biomonitoring; Subaward from Health Research, Inc.
Turkson, James
NCI
7R01CA128865-04
09/01/08
07/31/12
Therapeutic Application of Novel Stat3 Inhibitors in Breast
and Pancreatic Cancers
223,913
Ulrike, Peters
(FHCRC)/ Le
Marchand, Loic
(UHCC)
NCI
5U01CA137088-03
08/14/09
07/31/13
Colorectal Cancer Genome-Wide Associations Studies
Consortium/ Subaward Fred Hutchinson Cancer Research
Center
121,157
Vogel, CarlWilhelm
NCI
5U54CA143727-03
09/28/09
08/31/14
University of Guam/Cancer Research Center of Hawaii
Partnership
859,531
Vogel, CarlWilhelm
NCI
3U54C A143727-02S1
09/28/09
08/31/14
University of Guam/Cancer Research Center of Hawaii
Partnership Supplement
-
Wada, Randy
Hawaii
Community
Foundation
47026
06/08/10
12/08/11
Analysis of MYCN regulation by chromosome conformation
capture
Wada, Randy
AICR
09A018-REV2
01/01/10
12/31/11
Regulation of the MYCN Oncogene in Neuroblastoma
165,000
Wilkinson, Robert
Kapiolani
Clinical
Research
Center
CRA
07/01/10
06/30/12
Cooperative Research Agreement between Kakpiolani
Medical Center for Women & Children and University of
Hawaii Cancer Research Center of Hawaii
171,232
Wills, Thomas
NCI
5R01CA153154-02
07/01/10
04/30/15
Self-Control as a Moderator for Effects of Mass Media on
Adolescent Substance use
608,245
Wills, Thomas
NIDA
5R01DA021856-05
09/30/07
06/30/12
The Project Success Model: Evaluation of A Tiered
Intervention
646,328
Yang, Haining
NCI
1R01CA160715-01
07/28/11
05/31/16
The Role of HMGB1 in Pathogenesis of Mesothelioma
311,250
Yang, Haining
HCF - Leahi
Fund
08PR-42589
09/24/08
12/31/11
Mesothelioma Prevention and Early-Detection Studies
-
Zhang, Xiangian
(Vanderbilt
University Med
Cntr)/ Franke,
Adrian (UHCC)
NHBLI
5R01HL095931-03
03/15/10
01/31/14
Phytoestrogen and Endogenous Estrogen Exposure and Risk
of Stroke
181,285
Maskarinec,
Gertruad
NCI
5R25CA090956-09
02/01/01
08/31/13
Nutritional & Behavioral Cancer Prevention in a Multiethnic
Population
521,826
Maskarinec,
Gertruad
NCI
5R25CA090956-09S1
02/01/01
08/31/13
Nutritional & Behavioral Cancer Prevention in a Multiethnic
Population
105,741
Ramos, Joe
NIGMS
3R01GM088266-02S1
09/30/10
08/31/14
RSK2 Regulates Integrin-Mediated Adhesion and Migration
34,127
Page 15 of 16
401,256
50,579
50,000
UHCC Grants Office
01/26/2016
Totals
Page 16 of 16
19,878,036
1/27/2016
University of Hawaii Mail ­ Meetings of January 27 and 28
Board of Regents <[email protected]>
Meetings of January 27 and 28
Earl Stoner <[email protected]>
To: "[email protected]" <[email protected]>
Tue, Jan 26, 2016 at 6:18 PM
Dear Board of Regents members­ I am sending this written testimony as I am in S.E Asia on an extended trip
and cannot testify at your meetings. I am the immediate past president of the Board of the Friends of the UH
Cancer Center. As a board member for the past eight years, I am very well acquainted with the new Center and
its recent and past history. I believe the comprehensive report recently submitted to you presents a cogent and
well thought out plan and supporting documentation. This has not always been the case with prior documents released by the UH management team and others.
Much unfair criticism has been leveled at the UHCC by parties at Manoa and even some in the epidemiology
department of the Cancer Center. Largely this was the result of dissatisfaction with the former director. What I
found particularly disturbing was the fact that some of those in the UH faculty that felt they were being
mistreated felt they could go directly to the media with their concerns. The result was negative press for the
Center in general which affected the staff and researchers as well as seriously damaging fund raising capability.
Clearly, those employees have little respect for the entity that employs them and provides for their livelihood.
I have read the draft report presented to you and find it to be the first truly comprehensive study with factual
information on the UHCC since it's move into it's new quarters. I hope you will agree and give it the support
necessary both to back the administration and influence the legislature to continue financial support for the
Center. Let's remember that only five years ago the Board of Regents and the legislature supported a $100
million plus bond issue for the development of the new building with the consideration that bioscience,
particularly cancer research, was a necessary addition to expanding Hawaii's economy. Has that vision
changed? I think not.
While the report and recommendations require much work, this new Center is and should continued as a fledgling
business that needs time and support to succeed. Closing it or otherwise reducing its potential has some
onerous concerns for the university. Knee jerk reactions such as those proposed by the Center's opponents are
not solutions and may do more to damage an often impacted university. I hope you will join me and others that
support the UH Cancer Center as an important part of our university and our state. Thank you..... Earl Stoner
https://mail.google.com/mail/u/0/?ui=2&ik=5a046f4367&view=pt&search=inbox&msg=152814df3d02d5d2&siml=152814df3d02d5d2
1/1
1/27/2016
University of Hawaii Mail ­ Written Testimony for Meeting on January 28, 2016, 9:00 a.m.
Board of Regents <[email protected]>
Written Testimony for Meeting on January 28, 2016, 9:00 a.m.
Diane Ono <[email protected]>
To: [email protected]
Wed, Jan 27, 2016 at 5:45 AM
Dear Honorable Regents:
Attached please find my submission of written testimony in support of funding for the University of Hawai’i
Cancer Center. Thank you for considering this. Sincerely, Diane T. Ono
img­160127053349.pdf
1137K
https://mail.google.com/mail/u/0/?ui=2&ik=5a046f4367&view=pt&search=inbox&msg=15283c28c570eeb7&siml=15283c28c570eeb7
1/1